Market Closed -
Nasdaq
04:00:00 2025-01-17 pm EST
5-day change
1st Jan Change
22.36 USD
+1.36%
+5.82%
+18.68%
RBC Capital Downgrades Pacira BioSciences to Sector Perform From Outperform, Cuts Price Target to $14 From $37
August 12, 2024 at 08:11 am EDT
This article is reserved for members
Not a member ?
Free registration
Pacira BioSciences, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 10:30 AM
Jan. 15
Sector Update: Health Care Stocks Weaker Late Afternoon
Jan. 10
MT
Pacira Biosciences Reports Preliminary 2024 Revenue Rose, Outlines Five-Year Plan
Jan. 10
MT
Pacira BioSciences, Inc. Reports Preliminary Unaudited Revenue Results for the Year Ended December 31, 2024
Jan. 10
CI
Pacira Biosciences Gets FDA Clearance for Chronic Low Back Pain Treatment
Jan. 07
MT
Pacira BioSciences, Inc. Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block
Jan. 07
CI
RBC Raises Price Target on Pacira Biosciences to $18 From $16, Keeps Sector Perform Rating
Jan. 07
MT
Pacira Biosciences Shareholder DOMA Perpetual Capital Management to Nominate 4 Director Candidates
Dec. 11
MT
DOMA Perpetual Capital Management Intends to Nominate Candidates at 2025 Annual Meeting of Pacira BioSciences
Dec. 11
CI
Pacira BioSciences Receives US Patent for Exparel Composition
Dec. 03
MT
Pacira BioSciences, Inc. Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Nov. 14
CI
RBC Capital Adjusts Price Target on Pacira Biosciences to $16 From $15, Maintains Sector Perform Rating
Nov. 07
MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q3 EPS $0.83
Nov. 06
MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q3 EPS $0.83
Nov. 06
MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q3 Revenue $168.6M
Nov. 06
MT
Pacira BioSciences, Inc., Q3 2024 Earnings Call, Nov 06, 2024
Nov. 06
Tranche Update on Pacira BioSciences, Inc.'s Equity Buyback Plan announced on May 7, 2024.
Nov. 06
CI
Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 06
CI
Pacira BioSciences, Inc. Reports Goodwill Impairment for the Third Quarter Ended September 30, 2024
Nov. 06
CI
Pacira BioSciences, Inc. Reiterates Earnings Guidance for the Full-Year 2024
Nov. 06
CI
Pacira Biosciences Names Shawn Cross CFO
24-10-21
MT
Pacira BioSciences, Inc. Announces Chief Financial Officer Changes
24-10-21
CI
RBC Raises Price Target on Pacira BioSciences to $15 From $14, Keeps Sector Perform Rating
24-10-04
MT
Pacira BioSciences, Inc. Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
24-10-03
CI
Pacira BioSciences, Inc. Appoints Lauren Riker as Interim Chief Financial Officer, Effective October 1, 2024
24-09-27
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
PCRX: Dynamic Chart
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
More about the company
Last Close Price
22.36 USD
Average target price
20.43 USD
Spread / Average Target
-8.64%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1